Key takeaways
- The Washington Post reported on Oct. 7 that the administration is preparing a temporary stopgap to let some restricted peptides be sold while formal rules are written. 1
- The plan has not been announced, HHS did not comment, and the Post said the timing could change. 1
- The FDA's July advisory panel recommended six peptides for the compounding list, but a recommendation is not approval. 12
- Human evidence for the peptides involved is thin: the site rates KPV, MOTS-c and epithalon 2 out of 5, and Semax 3 out of 5.
Per the Washington Post, citing two people familiar with the matter, the administration is working on a stopgap that would let certain previously restricted peptides be dispensed by some compounding pharmacies while federal officials write new regulations. 1 It would be a shortcut around a process that normally takes much longer. This is a report, not an announcement, so details may change.
It matters because the evidence behind these products is still early, and because the rules for buying them are shifting fast.
What is confirmed and what is not
The confirmed part is the July vote. FDA's compounding advisory committee recommended six of seven peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epithalon and Semax. It voted against emideltide. 12 The FDA is not required to follow that advice. 1
Adding a substance to the list requires notice-and-comment rulemaking, which one law-firm analysis says could run into 2027 or 2028. 2 A second panel meeting on six more peptides is expected before February 2027. 2
The reported stopgap is the unconfirmed part. The Post said federal officials are seeking guardrails, but did not describe them. 1 The Alliance for Pharmacy Compounding said it asked FDA for interim enforcement discretion, along with patient disclosures, adverse-event reporting and data collection. 1
KPV: a gut-inflammation fragment with mouse data
KPV is a three-amino-acid fragment of a hormone called α-MSH. In mice it reduced colitis, and in cell studies it dampened inflammation signals. There are no published human trials. The panel vote on it was 8–6.
MOTS-c: early metabolic work
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Mouse studies show better insulin sensitivity and exercise capacity, and human work has only just started. The panel vote was 7–5. It is also prohibited in sport.
Semax: approved in Russia, not in the US
Semax is a registered medicine in Russia, mainly for stroke recovery, with small clinical studies behind it. Western randomized data is limited. The panel vote was 8–5, and it is the only one of these four not named on the WADA list.
Epithalon: the longevity claims rest on small studies
Epithalon is a four-amino-acid peptide from Russian research groups. Telomerase effects are seen in cultured cells and lifespan effects in rodents, but independent replication is lacking.
How the four compare
| Peptide | What it is | FDA status | Evidence (1–5) | Half-life | Banned in sport |
|---|---|---|---|---|---|
| KPV | Tripeptide fragment of α-MSH | Not approved; panel recommended | 2 | Not characterized in humans | Yes |
| MOTS-c | Mitochondria-derived peptide | Not approved; panel recommended | 2 | Short | Yes |
| Semax | ACTH-fragment analog | Not approved; panel recommended | 3 | Short (minutes) | No |
| Epithalon | Tetrapeptide | Not approved; panel recommended | 2 | Short | Yes |
Safety groups and enforcement point the other way
ECRI and the Institute for Safe Medication Practices said in May that patients using compounded wellness peptides lack reliable safety information. They cited testing of gray-market products that found purity from 5% to 75%. 3
Meanwhile, FDA warning letters dated Aug. 24 went to five online sellers. The agency said "research use only" labels did not change what the websites showed: products intended for human use. 45 Both signals sit alongside the reported loosening.
Quick hit: Lilly and retatrutide's classification
Eli Lilly plans to file for retatrutide in the first quarter of 2027, and it is fighting the FDA over whether the drug counts as a biologic. A biologic classification would permanently bar compounding. A court sided with the FDA on the amino acid count in September 2025, and Lilly has appealed. 6
The bottom line
A stopgap may widen access to a handful of peptides before the evidence catches up. For KPV, MOTS-c, Semax and epithalon, the human data remains limited. Wait for the official announcement and check the current status before assuming anything has changed.
This is educational information, not medical advice.
Sources
- HHS plans stopgap to allow sales of some unapproved peptides: Washington Post — Becker's Hospital Review, Oct. 8, 2026. https://www.beckershospitalreview.com/glp-1s/hhs-plans-stopgap-to-allow-sales-of-some-unapproved-peptides-washington-post/
- FDA balances peptide policy with enforcement against unlawful peptide sellers — Sheppard Mullin, Sept. 18, 2026. https://www.sheppard.com/insights/blogs/fda-balances-peptide-policy-with-enforcement-against-unlawful-peptide-sellers
- ECRI, ISMP warn of safety risks tied to peptides — Becker's Hospital Review, May 6, 2026. https://www.beckershospitalreview.com/pharmacy/ecri-ismp-warn-of-safety-risks-tied-to-peptides/
- NuScience Peptides LLC warning letter 733652 — FDA, Aug. 24, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
- RUO-ined: five peptide vendors learn that research use only is not a legal strategy — ArentFox Schiff, Sept. 18, 2026. https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy
- 5 things to know if retatrutide is classified as a biologic — AJMC, Oct. 7, 2026. https://www.ajmc.com/view/5-things-to-know-if-retatrutide-is-classified-as-a-biologic